Salesforce Stock Falls 15% YTD: Should Investors Keep Holding CRM?

Salesforce shares are down 15.1% year to date, but fiscal Q2 revenue rose 10.8% to $11.35 billion and cRPO increased 14% to $33.5 billion. The company raised fiscal 2027 revenue guidance to $46.10–$46.40 billion; Agentforce ARR exceeded $1.5 billion, up more than 240% year over year. The article recommends existing shareholders hold, while noting AI disruption and cautious enterprise spending risks, and says new investors may wait for clearer evidence of durable AI-driven growth.

Analysis

CRM: adoption metrics need to convert into durable economics. The market is pricing two competing effects: agents could make Salesforce’s workflow and data layer more valuable, but successful automation may also reduce paid seats. Agentforce usage and ARR growth do not yet resolve which effect dominates; usage can rise before customers expand paid deployments, while inference and implementation costs could dilute the economics. Longer contracts and cRPO provide near-term visibility, but can defer rather than eliminate renewal or seat-count pressure.

The key near-term distinction is organic demand versus acquisition-supported growth. Informatica adds scale and strengthens the data-platform pitch, but reported growth that relies on acquired revenue is less persuasive evidence of a CRM recovery. Watch organic subscription growth, cRPO conversion, paid Agentforce expansion, and operating cash flow/margins together. If AI bookings grow while traditional seat expansion weakens, headline AI adoption could conceal a mix shift rather than incremental demand.

Over 1–3 months, guidance and customer monetization evidence matter more than activity metrics; over 6–18 months, the decisive test is whether Salesforce can sell agents and data products without materially cannibalizing core seats or sacrificing margins. A low relative multiple offers some cushion, not a floor: forward earnings estimates may not yet reflect either risk. The sector selloff also raises the possibility of indiscriminate de-rating, but peer weakness alone is not a catalyst for CRM rerating.

Key Decisions for Investors

• Do not chase the AI usage statistics. Keep existing exposure sized conservatively; treat a new long as conditional on the next results showing paid Agentforce expansion alongside stable organic subscription growth and margins.
• Potential relative-value setup: consider a small, beta-aware long CRM versus a short broad software exposure only if CRM’s organic cRPO and monetization metrics remain firm while sector multiples stay under pressure. Avoid an unhedged pair based solely on the article’s valuation comparison.
• Track quarterly: organic cRPO growth and conversion, paid Agentforce ARR/bookings versus usage, seat or renewal trends, and cash-flow/margin performance. Separate Informatica’s contribution from organic growth before upgrading the thesis.
• Falsify the constructive view if organic growth or cRPO decelerates, AI activity fails to convert to paid deployments, or margins weaken as AI usage scales. Conversely, sustained monetization with stable core-seat economics would support adding exposure; absent that evidence, there may be no immediate trade.